Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

First-in-human, Phase I/II, Multicenter, Open-Label Study of EMB-01 in Patients With Advanced/Metastatic Solid Tumors

NCT03797391 is registered in ClinicalTrials.gov with Shanghai EpimAb Biotherapeutics Co., Ltd. as lead sponsor.

NCT NCT03797391
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03797391 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
First-in-human, Phase I/II, Multicenter, Open-Label Study of EMB-01 in Patients With Advanced/Metastatic Solid Tumors
Lead sponsor
Shanghai EpimAb Biotherapeutics Co., Ltd.
Phase
Phase 1/2
Overall status
Unknown status
Start date
December 13, 2018
Completion date
January 15, 2026
Enrollment
186 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasm metastasis, neoplasms, non-small-cell lung cancer